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Abstract
Background: In recent years, the use of MRI in patients with Crohn’s disease (CD) has increased. However, few data
are available on how MRI parameters of active disease change during treatment with anti-TNF and whether these
changes correspond to symptoms, serum biomarkers, or endoscopic appearance. The aim of this study was to
determine the changes over time in MRI parameters during treatment with anti-TNF in patients with CD, and to
verify the correlation between MRI score, endoscopic appearance and clinical-biological markers.
Methods: We performed a prospective single centre study of 27 patients with active CD (18 males and 9 females;
median age of 27,4 ys; age range, 19–49). All patients underwent ileocolonoscopy and MRI at baseline and
26 weeks after anti-TNF therapy. Endoscopic severity was graded according to the Simple Endoscopic Score for
Crohn’s Disease (SES-CD) and Magnetic Resonance Index of Activity (MaRIA) was calculated. Patients underwent
clinical evaluation (CDAI) and the C-reactive protein (CRP) level was measured. The associations between variables
were assessed with Pearson’s bivariate correlation analysis.
Results: A total of 135 intestinal segments were studied. The median patient age was 27,4 years, 67 % were male
and the mean disease duration was 6,1 years. For induction of remission, 18 patients were treated with infliximab
and 9 with adalimumab. The mean SES-CD and MaRIA scores significantly changed at week 26 (SES-CD: 14,7 ± 8,9
at baseline vs. 4,4 ± 4,6 at 26 weeks - p < 0.001; MaRIA: 41,1 ± 14,8 at baseline vs. 32,8 ± 11,7 at 26 weeks - p < 0.001).
Also the CDAI and serum levels of CRP decreased significantly following treatment (p < 0.001). The overall MaRIA
correlated with endoscopic score and with clinical activity (CDAI) both at baseline and at week 26 (p < 0.05). The
correlation between overall MaRIA and CRP was significant only at week 26 (p < 0.001).
Conclusions: The MaRIA has a good correlation with SES-CD, a high accuracy for prediction of endoscopic mucosal
healing and is a reliable indicator to monitor the use of TNF antagonists in patients with CD.
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Background
Crohn’s disease (CD) is a disabling transmural and seg-
mental chronic inflammatory bowel disease (IBD) with a
relapsing and remitting course. Its inflammatory lesions
can affect the entire gastrointestinal (GI) tract leading to
various intestinal (internal and external fistulas, intes-
tinal strictures, abdominal and perianal abscesses) and
extra-intestinal manifestations [1].
Although its aetiology is still unknown considerable
progress has been made in the understanding of the mo-
lecular mediators and mechanisms of tissue injury.
Current treatment protocols, based on the use of drugs
with a gradually increasing strength of action, are aimed
at modulating the complex inflammatory events leading
to intestinal injury [2].
The proinflammatory cytokine Tumor Necrosis Factor
(TNF) alpha is a key mediator of inflammation associated
with CD [3] and the recent development of antibody to
TNF alpha (anti-TNF) drugs has led to significant improve-
ments in the medical treatment of these patients [4, 5].
These antagonists of TNF-alpha, i.e. infliximab (IFX) and
adalimumab (ADA), are effective in inducing as well as
maintaining clinical remission in patients with moderately-
to-severely active CD disease who are refractory to trad-
itional treatments (corticosteroids and immunosuppressive
drugs). Complete disappearance of mucosal ulcerations is
associated with favourable outcome, and after initiation
with anti-TNF, mucosal healing (MH) leads to a decrease
both in relapse rates and in disease related hospitalization,
reducing the need for surgery [6].
Unfortunately, the proven clinical efficacy of anti-TNF
drugs is contrasted with the elevated frequency of pre-
mature relapses on discontinuing treatment once main-
tained remission of the disease is achieved [7]. This
phenomenon is attributed to the persistence of inflam-
matory activity despite an apparent positive clinical re-
sponse [8]. In fact, CD is a typically transmural disease
and its activity can be difficult to accurately evaluate.
Therefore, for assessing CD activity, for tailoring ther-
apy, and for measuring treatment response, objective de-
termination of inflammatory activity should be essential.
The gold standard for assessment of luminal inflamma-
tion in CD is endoscopy with biopsies, which can evalu-
ate MH but it is invasive, exposes patients to inherent
procedural risks, and is unable to assess the mid-small
intestine [9]. Symptom-based disease activity indexes are
subjective by design and often unreliable [10].
Cross-sectional imaging can serve as an alternative or
an adjunct to ileocolonoscopy to evaluate therapeutic re-
sponse and transmural healing. Computed tomographic
and magnetic resonance enterography have been re-
ported to be useful modalities for the evaluation of lu-
minal inflammation and extra intestinal complications in
CD. MRI can be performed without radiation exposure,
making it the preferred imaging technique for the evalu-
ation of CD [11]. To our knowledge the effects of the
biological agents on transmural inflammation and their
resulting imaging are largely unknown.
The primary aim of this study was to, therefore, deter-
mine the changes over time in MRI parameters during
treatment with anti-TNF in patients with CD. Secondary
aim is to examine whether radiologic response to anti-




Between April 2012 and April 2015, 27 outpatients diag-
nosed with CD according to the Lennard-Jones criteria
(Table 1) [12], were prospectively studied at single
centre. The patient cohort comprised 18 males and 9
females, with a median age of 27,4 years (age range, 19–
49). The median disease duration was 6,1 years (mean
SD, 2,2). Inclusion criteria were age ≥ 18, moderate-to-
severe intestinal disease (Crohn’s Disease Activity Index –
CDAI - score > 220 points) and elevated C-reactive pro-
tein (CRP) level (>5 mg/l). Exclusion criteria were active
or latent tuberculosis, contraindications for MR, treat-
ment with more than 15 mg of systemic corticosteroids
(prednisone equivalent) within the 2 weeks prior to base-
line MRI, documented abdominal abscess or internal fis-
tula as well as medical contraindications for anti TNF
therapy.
Table 1 Lennard-Jones anatomic criteria for the diagnosis of







Upper gut + + + +
Anus + + +
Discontinuous + + + +
Transmural inflammation +
Fissure + +
Abscess + + +
Fistula + + +






aA diagnosis of Crohn’s disease requires 3 positive findings, or one positive
finding with granulomas on histology
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The anti-TNF treatment consisted of administering
an induction regimen, either with IFX or ADA in
the case of patients who had previously been treated
with IFX and who had presented complications in its
administration. The induction regimen for IFX con-
sisted of administering three intravenous doses of
5 mg/Kg in weeks 0, 2 and 6, and maintenance every
8 weeks thereafter. The induction regimen for ADA
consisted of an 160 mg subcutaneous injection as an
initial dose, followed by 80 mg after 2 weeks and
40 mg every other week thereafter [5]. After obtain-
ing written informed consent, endoscopy (reference
standard), clinical-biological assessment and MRI
were performed in all patients prior to the first anti-
TNF drugs infusion and at week 26. Ileocolonoscopy
and MRI were performed within a maximum interval
of 7 days and the time gap between these tests and
the start-end of anti-TNF therapy was to a max-
imum of 3 days.
Endoscopic examination
Ileocolonoscopy was considered the reference standard
for the evaluation of IBD extension and severity. In all
cases endoscopy was performed under anaesthesia by
experienced endoscopist in IBD (NDV) using standard
equipment (CV-180; Olympus, Japan) and following the
standard protocol used in clinical practice (colonic
cleansing with 4 L polyethylene glycol plus low-fiber diet
3 days before). The length of terminal ileum evaluated
on colonoscopy ranged from 5 to 15 cm. Quantification
of endoscopic lesions was calculated globally and per
segment using the Simple Endoscopic Score for Crohn’s
Disease (SES-CD). For accuracy of endoscopic data col-
lection, endoscopist completed the SES-CD on a prede-
fined scoring sheet immediately after finishing the
procedure.
For the grading of endoscopic findings with SES-CD,
the bowel was divided into 5 segments: terminal ileum;
right, transverse, and left colon; and rectum. Four endo-
scopic variables in the 5 segments were scored from 0 to
3 [13]. The variable “presence and size of ulcers” was
scored 0 when no ulcers were present, 1 for small ulcers
(diameter, 0.1–0.5 cm), 2 for medium-sized ulcers (diam-
eter, 0.5–2 cm), and 3 for large ulcers (>2 cm). The vari-
able “extent of ulcerated surface” was scored 0 when no
ulcers were present, 1 when extent was <10 %, 2 when
extent was 10 % to 30 %, and 3 when extent was >30 %.
The variable “extent of affected surface” was scored 0
if none, 1 when <50 %, 2 when 50 % to 75 %, and 3
when >75 %. The variable “presence and type of nar-
rowing” was scored 0 when no narrowing was present,
1 for a single passable narrowing, 2 for multiple passable
narrowed areas, and 3 for a non-passable narrowing. The
resulting score was (Table 2): SES-CD = sum of all vari-
ables – 1,4 × number of affected segments.
The SES score can range from 0 to 60, with a higher
score indicating more severe disease. Investigator report-
ing the endoscopic lesions was blinded to the results of
the MRI examination.
Magnetic resonance enterography
All MRI examinations were performed in the supine
position with a 1.5 T magnet (Achieva, Philips Medical
System, Eindhoven, The Netherlands) equipped with a
phased-array-16-elements coil. 1 h prior to MRI, all pa-
tients received orally 1000–1500 ml of iso-osmotic PEG
solution, which was freshly prepared by dissolving in
water a granular powder containing PEG (58.32 g), so-
dium sulphate (5.69 g) sodium bicarbonate (1.69 g), so-
dium chloride (1.46 g) and potassium chloride (0.74 g)
(Selg 1000, Promefarm, Milan, Italy). In order to ensure
an adequate intestinal distension, a coronal T2 scan was
performed after 30 min after oral contrast administra-
tion. If the minimum diameter of the small bowel loops
was 15 mm o larger, the bowel distension was judged
satisfactory and MRI was continued after intravenous
administration of 20 mg N-butylscopolamine (Buscopan,
Boringher Ingelheim, Ingelheim am Rhein, Germany) in
order to suppress small bowel peristalsis and avoid mo-
tion artifacts.
Then, the acquisition protocol outlined in Table 3 was
performed. 3D T1-weighted high-resolution isotropic
volume excitation (THRIVE) before and 30–40s, 70–90s
and 120–140 s after intravenous administration of
0.2 ml/kg body weight of gadolinium chelate (Gd-DTPA,
Magnevist, Schering AG, Germany) and finally a T1-
weighted water selective (WATS) fat-saturated sequence
in the axial plane late after injection were acquired.
Image analysis was performed by one experienced
radiologist (LPS) and one junior radiologist (SR) using a
dedicated postprocessing workstation (ViewForum, Phi-
lips Medical System, Eindhoven, The Netherlands). To




















Sum of all variables TOT
Affected segments ☐ ☐ ☐ ☐ ☐
TOT – 1.4 × (number of affected segments) = SES-CD
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allow comparison with endoscopic score, the same div-
ision into segments was considered. The small and large
bowel were examined to detect the segment with the
most severe lesions on the basis of the following criteria:
bowel wall thickness (mm), presence of mucosal ulcers
(defined as deep depressions in the mucosal surface), pres-
ence of mural oedema (hyperintensity on T2-weighted se-
quences of the bowel wall relative to the signal of the
psoas muscle), presence of enlarged regional mesenteric
lymph nodes, presence of fistula or abscess, and relative
contrast enhancement (RCE) of the intestinal wall. Quan-
titative measurements of wall signal intensity (WSI) were
obtained from the areas with the greatest thickening [re-
gion of interest (ROI)] before and after intravenous injec-
tion of gadolinium (70 s). RCE was calculated according
to the following formula: RCE = [(WSI postgadolinium −
WSI pregadolinium)/(WSI pregadolinium)] × 100 × (SD
noise pregadolinium/SD noise postgadolinium). As de-
fined by Rimola et al. [14, 15] for measurement of thera-
peutic response by means of MRI and to allow comparison
with the reference standard (SES-CD), the MaRIA in each
segment was calculated according to the following formula:
1.5 × wall thickening (mm) + 0.02 × RCE (relative contrast
enhancement) + 5 × oedema + 10 × ulcers.
The global MaRIA score was calculated as the sum of
the MaRIA in ileum, right colon, transverse colon, left
colon-sigmoid and rectum.
Response assessment
In order to quantify disease activity the SES-CD and
the MaRIA were calculated at baseline and 26 weeks
after treatment initiation. MH was defined as the ab-
sence of mucosal ulcerations at week 26 in patients
who had mucosal lesions endoscopically confirmed
at baseline [16]. The endoscopic response was de-
fined as a decrease from baseline in SES-CD score
of at least 5 points and at least 50 % [17] with a
complete endoscopic remission (MH) when SES-CD
score ≤ 2 [18]. In MRI examinations the MH was de-
fined as the complete disappearance of intestinal le-
sions at week 26, while the radiologic response was
defined as an overall MaRIA score reduction of at
least 9.7 points.
In addition, the response to treatment was assessed
both clinically as well as biologically by calculating the
CDAI and the nephelometric determination of the
serum concentration of CRP. The CDAI is a numerical
calculation derived from the sum of products from a list
of 8 items (Table 4), and multiplied by weighting factors
for each item to define the severity of “disease activity”
in patients with CD [19]. Three categories were identi-
fied to define the clinical-biological response: (a) Lack of
response when the CDAI and CRP levels increased or
did not change; (b) Partial response when the CDAI de-
creased by more than 70 points and CRP levels de-
creased but did not restore to normal and (c) Remission
when the CDAI was lower than 150 points and CRP
levels were normal.
Statistical analysis
Quantitative variables are given as means and standard de-
viation (SD) and proportions are expressed as percentages
and 95 % confident intervals (CIs). Differences in quantita-
tive measures were tested by Student’s test. The associa-
tions between continuous variables were evaluated with
Pearson’s bivariate correlation analysis. To determine the
best cut-off value both of the overall MaRIA and of the Δ
MaRIA scores for predicting endoscopic remission (SES-
CD score ≤ 2) receiver operating characteristic (ROC)
curves were calculated. Inter-observer agreement between
paired evaluations of MR by two radiologists (LPS and SR)
was performed with Pearson correlation coefficient.














5 5 5 4 1.5 5
FOV (mm) 450x450 400x400 450x450 400x400 420x420 450x450
TR (ms) 1200 1200 140 3,7 2.3 346
TE (ms) 80 80 4,6/2,3 1,9 4.7 6.6
Flip angle 90 90 80 40 10 70
Table 4 CDAI items and weighting factors
Item (daily sum per week) Weighting factor
Number of liquid or very soft stools 2
Abdominal pain score in one week (rating, 0–3) 5
General well-being (rating, 1–4) 7
Sum of physical findings per week: 20
Arthritis/arthralgia
Mucocutaneous lesions
(e.g. erythema nodosum, aphthous ulcers)
Iritis/uveitis
Anal disease (fissure, fistula, etc.)
External fistula (enterocutaneous,
vesicle, vaginal, etc.)
Fever over 37.8 °C
Antidiarrheal use 30
Abdominal mass (no = 0, equivocal = 2, yes = 5) 10
47 minus hematocrit (males) or 42 minus
hematocrit 6 (females)
6
1-x (1-body weight divided by a standard weight) 1
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The Statistical Package for the Social Sciences (version
21, SPSS Inc, Chicago, Ilinnois, USA) was used to de-
scribe and analyse the data, considering values of p <
0.05 as significant.
Results
27 consecutive patients were included in the study for a
total of 135 segments explored by ileocolonoscopy and
then evaluated by MRI. Baseline characteristics of the
patients are given in Table 5. Before the administration
of the anti-TNF treatment, all patients had a CDAI > 220
points, a CRP level greater than 5 mg/l and a SES-CD >
3. For induction of remission, 18 patients (67 %) were
treated with IFX and 9 (33 %) with ADA.
The correlation between overall SES-CD and overall
MaRIA was good at baseline (p = 0.03) and very high at
week 26 (p < 0.001) (Fig. 1).
A significant correlation between overall MaRIA and
CDAI, including both baseline and week 26, was observed
(p = 0.03; p < 0.001, respectively). The correlation between
overall MaRIA and CRP was significant only at week 26
(baseline: p = 0.4; week 26: p < 0.001). A significant correl-
ation of the Δ MaRIA score was observed with Δ SES-CD
(p < 0.001), Δ CDAI (p < 0.001) and Δ CRP (p < 0.001).
The administration of the anti-TNF drug induced
endoscopic response in 16 patients (59 %) and among
these a complete disease remission/MH (SES-CD ≤ 2)
occurred in 13 patients (48 %). 10 patients (37 %)
showed a stable or slightly lower SES-CD compared to
baseline. Only 1 patient (4 %) had a SES-CD slightly in-
creased at the end of the study.
Using a cut-off point of 30.8 the overall MaRIA was
found to have a high accuracy for prediction of endo-
scopic MH (SES-CD score ≤ 2) with an area under
the ROC curve of 0.967, sensitivity of 93 % and spe-
cificity of 77 % (Fig. 2). At week 26 the overall
MaRIA score was < 30.8 in 13 patients (48 %; Fig. 3).
A Δ MaRIA score ≥ 9.7 had a good diagnostic accuracy
for predicting endoscopic remission/MH with sensitivity
of 77 % and specificity of 57 % (area under the curve
0.580; 95 % CI: 0.634–0.944). At week 26 the overall
MaRIA score decreased of at least 9.7 points in 10 pa-
tients (37 %) while increased in 4 patients (15 %). In the
remaining 13 patients (48 %) the overall MaRIA score
decreased by less than 9.7 points compared to baseline
(Fig. 4).
Clinical-biological assessment of therapeutic response
demonstrated that a CDAI < 150 at week 26 was
achieved in 12 patients (44 %) and CRP levels restored
to normal in 21 patients (78 %). At week 26, CRP levels
reduced in 6 patients (22 %) and 3 patients (12 %) had a
CDAI decrease of more than 70 points, defined as a par-
tial response. Lack of response with CDAI increased or
not changed was observed in remaining 12 patients
(44 %). No patients showed an increase of CRP levels.
The results of the endoscopic, MRI and clinical-
biological changes induced by the treatment are shown
in Table 6.
In terms of endoscopy and MRI, there was a statisti-
cally significant reduction both in SES-CD and in
MaRIA score (p < 0.001). Also the CDAI and serum
levels of CRP decreased significantly following treatment
(p < 0.001).
We observed high interobserver agreement for the over-
all MaRIA score both at baseline and at week 26 (κ = 0.93,
s.e. = 0.88; κ = 0.95, s.e. = 0.98, respectively). Accuracy
rates for the overall MaRIA score were 92 % at baseline
and 96 % at the end of the study.
Discussion
Since the beginning of anti-TNF therapy, MH has be-
come an important predictor of long-term disease out-
come in IBD. MH during scheduled anti-TNF therapy
reduces need for surgery and hospital treatment signifi-
cantly [20]. Accordingly, the assessment of therapeutic
efficacy requires close monitoring of the mucosa and the
bowel wall. To date, ileocolonoscopy remains the gold
standard for assessing disease remission in CD, and in
the present study we prefer to use the SES-CD since it is
a reproducible index for this evaluation [13, 21], easier
and faster to calculate than Crohn’s Disease Endoscopic
Index of Severity (CDEIS). In fact CDEIS, although it
has proven to be a reliable and reproducible marker of
MH in a number of therapeutic trials [22–24], is rather
time consuming and elaboration of the score requires
analogue scale transformation. These characteristics
make CDEIS unsuitable for everyday clinical practice
and also its use can be complex in clinical trials. Never-
theless, endoscopy remains an invasive procedure with
potential complications [25], can be felt as a problem by
Table 5 Baseline characteristics of the patients
Patients n = 27
M/F 18/9
Age at diagnosis [median] 27,4
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CD patients and does not reflect the overall burden of
the disease [26].
As the small bowel is difficult to reach with conven-
tional endoscopy, several non-invasive tools have been de-
veloped in the last two decades in the investigation of CD.
MRI is probably to date the best alternative, owing to its
nonionizing characteristics and high performances espe-
cially in detecting signs of intestinal inflammation [27]. In
particular, MRI has great potentials in characterization of
the CD, being able to assess parameters such as parietal
thickening, hypervascularity (comb signs), mesenteric
fibro-fatty proliferation and others [11]. Since CD is a
trans-mural disease, the use of MRI represent an import-
ant step in the diagnostic, therapeutic and prognostic
management of the disease, because the mucosal lesions
assessable by endoscopy represents only the tip of the in-
flammatory process. These findings call for revision of the
current understanding of “intestinal healing” in the treat-
ment of CD. MRI may be in fact employed to determine
microscopic structural wall changes, including edema and
fibrosis, hypervascularity, capillary permeability, and likely,
in the next years, specific molecular abnormalities, ex-
tending beyond the concept of “mucosal healing” [27].
Recently Rimola and co-workers developed the MaRIA
score, which is able to assess inflammation in ileal and
colonic CD [14, 15]. The MaRIA score is a validated
index for describing the severity of inflammation, but it
is not a gold standard for describing CD, which is much
more complex. Despite this limitation, MRI in CD can
be considered as the most validated tool for evaluating
inflammation.
In our study, we evaluated MRI findings, before and
after medical therapy with anti-TNF, and the correlation
between endoscopic assessments, clinical-biological re-
sponses and MRI modifications. The first study assessing
the responsiveness of MRI in patients with CD was pub-
lished in 1999 [28]. In this small study, 8 patients with
active CD were examined before and after treatment
Fig. 1 Correlation between overall MaRIA score and SES-CD at week 26
Fig. 2 Receiver operating characteristic (ROC) curves of the overall MaRIA (a) and of Δ MaRIA (b) scores to predict endoscopic remission/MH
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with corticosteroids using low-field magnetic resonance
(1.0 T). The MRI parameters that showed a significant
reduction during treatment were contrast enhancement
(p < 0.001) and wall thickness (p = 0.03), which is in
agreement with the results of the current study.
More recently, Ordas et al. [29] performed a prospective
multicentre study of 48 patients with active CD, examining
patients who underwent ileocolonoscopy and MRI at base-
line and 12 weeks after treatment with steroid or tumor ne-
crosis factor inhibitor (specifically ADA). The primary end
points for the study were determining the accuracy of MRI
in identifying ulcer healing (defined as the disappearance of
ulcers on endoscopic exam) and the endoscopic remission
(quantified using CDEIS <3.5). MRI had a high diagnostic
accuracy for both predicting endoscopic ulcer healing, with
sensitivity of 75 % and specificity of 80 %, and endoscopic
remission, with sensitivity of 83 % and specificity of 84 %.
Our data showed similar MRI diagnostic accuracy for pre-
dicting endoscopic remission/MH with a higher sensitivity
(93 %) and a slightly lower specificity (77 %). These com-
parable results were obtained in spite of our study was a
single centre using a 1.5 T MR unit while the Ordas was a
multicentre study performed with 3.0 T scanner, which
should have a better signal and higher spatial resolution.
Moreover, the results were not influenced despite the use
of different endoscopic indexes, different therapeutic strat-
egies and the lack of colon distension by instillation of
water through a rectal catheter.
Similar to our study, Van Assche and co-workers [30]
recruited only anti-TNF-naïve patients in a multicentric
and prospective trial evaluating the effects of IFX ther-
apy on MRI ileal CD lesions. This pilot study included
15 patients that were studied at baseline, 2, and 26 weeks
after starting IFX induction and maintenance therapy.
The authors concluded that normalization of MRI find-
ings is rare after IFX therapy. This is apparently discrep-
ant with the observations of the current study, in which
normalization of MRI findings paralleled endoscopic and
clinical responses. The reasons for this discrepancy
might include the fact that the study by Van Assche et
al. used a different activity index and it only assessed
ileal disease in a limited sample size.
In the current study a prospective series of patients
with ileo-colonic CD was assessed in which a 59 %
rate of endoscopic partial or complete response was
achieved using an anti-TNF induction therapy. This
percentage is similar to those described in the litera-
ture [31]. In our series, a reduction of the overall
MaRIA score was found in 48 % of patients and a signifi-
cant improvement in Δ MaRIA score was found in 37 % of
patients following the treatment. A complete disappearance
of MRI alterations was found only in 5 patients. As ex-
pected, the MRI improvement was significantly related to
the endoscopic and the clinical-biological response in such
a way that it only occurred in patients who responded to
the treatment. These data support the reliability of MRI as
Fig. 3 Patient with CD of the terminal ileum in treatment with IFX. At baseline, MRI (a and b) detected moderate inflammatory lesions of
the terminal ileum, with wall thickening accompanied by oedema, irregularity of the mucosal surface and hyperenhancement after
intravenous contrast administration (Overall MaRIA score = 49). Baseline endoscopy of the same segment confirmed the presence of
serpiginous, longitudinal ulcerations (c; SES-CD = 20). At week 26, the terminal ileum achieved healing at both MRI (d and e; Overall
MaRIA score = 19,2; Δ MaRIA score = 29,8) and endoscopy (f; SES-CD = 0)
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a tool in assessing response to treatment in-patient with
CD.
This study has its limitations. In a purely observa-
tional design, our endoscopic end-points MRI, la-
boratory and clinical findings present the outcome of
a heterogeneous CD patient group during treatment
with anti-TNF in real-life clinical practice. Con-
founding relevant factors are our use of both ADA
and IFX and their varying dosages and the small
proportion of CD patients.
Conclusions
In conclusion, our data demonstrate that MaRIA
have a high correlation both with SES-CD and with
clinical-biological activity of the disease. According
to Tielbeek et al. [32], MRI is a valid and reliable
technique to monitor the use of TNF antagonists in
clinical practice and it provides an accurate measure
for prediction of endoscopic MH in patients with CD.
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induced by anti-TNF treatment
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SES-CD [mean (SD)] 14,7 (8,9) 4,4 (4,6)
Overall MaRIA [mean (SD)] 41,1 (14,8) 32,8 (11,7)
CDAI [mean (SD)] 423,7 (71,1) 238,5 (140,1)
CRP [(mg/l) mean (SD)] 25,1 (23,6) 4,6 (5,6)
Fig. 4 Patient with CD of the distal ileum, left and transverse colon in treatment with IFX. At baseline, MRI (a and b) detected severe
inflammatory lesions of the terminal ileum, with marked wall thickening accompanied by oedema, extensive irregularity of the mucosal surface
and stratified hyperenhancement after intravenous contrast administration. A moderate wall thickening of the left colon is also present with
hyperenhancement after intravenous contrast administration (Overall MaRIA score = 62,7). Baseline endoscopy at the distal ileum revealed the
presence of stricturing, cobblestone appearance of the mucosal surface (c; SES-CD = 33). At week 26, the distal ileum continues to present at MRI
a moderate wall thickening with mild hyperenhancement after intravenous contrast administration (d and e; Overall MaRIA score = 52,6; Δ MaRIA
score = 10,1) Endoscopy of the same segment shows irregular longitudinal ulcers (f; SES-CD = 10)
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